Biohaven Licenses Kv7 Ion Channel Platform to SK Biopharmaceuticals Globally

AI-generated NewsSnap summary based on source reporting.
Published: 2026-08-26
Category: business
Source: SEC.gov (Form 8-K)
Original source

Biohaven Bioscience Ireland Limited and SK Biopharmaceuticals Co., Ltd. have finalized a global licensing agreement for Biohaven's Kv7 ion channel platform. This platform includes opakalim, a key candidate in development for epilepsy treatment. The collaboration aims to advance the therapeutic potential of this technology on a global scale.

Want more?

Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.

Open NewsSnap.ai